A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2

Atherosclerosis

Volumn 224, Issue 1, 2012, Pages 150-153

  Santos, Raul D ^a   Waters, David D ^b   Tarasenko, Lisa ^c   Messig, Michael ^c   Jukema, J Wouter ^d   Chiang, Cheng Wen ^e   Ferrieres, Jean ^f   Foody, JoAnne M ^g  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER INC   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CATHAY GENERAL HOSPITAL   (Taiwan)

^f CHU RANGUEIL   (France)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Coronary heart disease; LDL cholesterol; Non HDL cholesterol; Risk factors; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET THERAPY; DYSLIPIDEMIA; FEMALE; GOAL ATTAINMENT; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA;

ADULT; AGED; CANADA; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DYSLIPIDEMIAS; EUROPE; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; LATIN AMERICA; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 84865388510     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.06.052     Document Type: Article

References (15)

1. Blaha M.J., Blumenthal R.S., Brinton E.A., Jacobson T.A. National lipid association task force on non-HDL cholesterol. The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol 2008, 2:267-273.
2. Emerging Risk Factors Collaboration, Di Angelantonio E., Sarwar N., Perry P., et al. Major lipids, apolipoproteins, and risk of vascular disease. J Am Med Assoc 2009, 302:1993-2000.
3. Kastelein J.J., van der Steeg W.A., Holme I., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008, 117:3002-3009.
4. Robinson J.G., Wang S., Smith B.J., Jacobson T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009, 53:316-322.
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106:3143-3421.
6. Genest J., McPherson R., Frohlich J., et al. 2009 Canadian cardiovascular society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009, 25(10):567-579.
7. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Atherosclerosis 2011, 217:3-46.
8. Waters D.D., Brotons C., Chiang C.W., et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120:28-34.
9. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009, 120:1640-1645.
10. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003, 24:1601-1610.
11. Genest J., Frohlich J., Fodor G., McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003, 169:921-924.
12. Yusuf S., Reddy S., Ounpuu S., Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001, 104:2746-2753.
13. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
14. Davidson M.H., Maki K.C., Pearson T.A., et al. Results of the national cholesterol education (NCEP) program evaluation project utilizing novel E-technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing group recommendations. Am J Cardiol 2005, 96:556-563.
15. Virani S.S., Woodard L.D., Landrum C.R., et al. Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the adult treatment panel III guidelines. Am Heart J 2011, 161:1140-1146.